GHK-Cu (Copper Peptide)

This page covers two different things. Topical GHK-Cu is a well-established cosmetic ingredient with real human evidence. Injectable GHK-Cu — the form marketed in fitness and "peptide therapy" contexts — is not FDA-approved and has no published human clinical trials behind it. Don't read topical evidence as support for injectable use; they are not the same product or the same evidence base. This page is not dosing or usage guidance for either form, and not a recommendation to use either.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine bound to copper) found in human plasma, saliva, and urine, where levels decline with age. Proposed mechanisms include stimulating collagen and glycosaminoglycan production, supporting antioxidant enzyme activity, and modulating wound-healing and tissue-remodeling pathways — mechanisms studied almost entirely in skin, which is why the strongest evidence is for topical, not systemic, use.

Topical copper peptide (often listed as "Copper Tripeptide-1") has decades of published human skin research behind it, including controlled trials on photoaging, wrinkle reduction, and collagen synthesis — for example, a widely cited 2002 trial (Leyden et al.) and more recent gel-formulation studies reporting measurable increases in skin collagen density over several months. This is genuine human clinical evidence, and it's why topical GHK-Cu is regulated in the US as a cosmetic ingredient, not a drug — a meaningfully different, better-supported situation than the injectable form below.

Injectable GHK-Cu — the form sold and marketed for systemic "anti-aging," recovery, or fitness use — rests on a fundamentally different, much thinner evidence base. The systemic effects claimed for it (connective-tissue remodeling, lung-tissue protection, neuroprotection) come from animal models; there are no published human clinical trials of injectable GHK-Cu. Topical skin research does not transfer to injectable systemic use — different route, different exposure, different (and largely unstudied) risk profile.

Injectable GHK-Cu is not FDA-approved for any use and is a separate regulatory question from the topical cosmetic form. Injectable-route GHK-Cu was among the peptides the FDA removed from its Category 2 "significant safety risk" compounding list effective April 22, 2026 — but that removal is not approval, and unlike BPC-157, TB-500, and several other peptides, injectable GHK-Cu was not part of the July 2026 advisory committee meeting that reviewed peptides for the actual compounding-permitted list; FDA has indicated it plans a separate future meeting to address it. In practical terms: still unapproved, still without human injectable trial data, and further from a compounding decision than several of its Category 2 peers.

FDA — Bulk Drug Substances Used in Compounding →

FDA — Bulk Drug Substances Used in Compounding Under Section 503A